Go Pro
OTCMKTS:RCAR

RenovaCare (RCAR) Stock Price, News & Analysis

RenovaCare logo

About RenovaCare Stock (OTCMKTS:RCAR)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
160 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RenovaCare, Inc. is a clinical‐stage regenerative medicine company focused on developing and commercializing products for the treatment of severe skin injuries and chronic wounds. The company’s core technology, the TransForm™ device, is an autologous cell therapy system designed to harvest, process and deliver a patient’s epidermal cells directly to wound sites. By leveraging a proprietary vacuum technology, TransForm™ enables clinicians to create and apply a living skin spray that aims to accelerate healing in acute burns, diabetic foot ulcers and other complex skin defects.

RenovaCare holds a robust patent portfolio covering its TransForm™ platform, which it is advancing through clinical trials and regulatory pathways in the United States. The company’s research and development efforts are focused on validating the safety, efficacy and ease of use of its handheld device, with the goal of securing regulatory clearance for broader commercial use. RenovaCare’s product pipeline is complemented by ongoing preclinical studies to explore additional indications, including chronic wounds and dermatological conditions where enhanced skin regeneration could offer significant benefits.

Headquartered in Newport Beach, California, RenovaCare serves patients and healthcare providers in North America, with plans to expand into key international markets. The company collaborates with burn centers, wound care specialists and academic institutions to generate clinical data and refine treatment protocols. Through strategic partnerships and potential licensing arrangements, RenovaCare aims to establish a scalable manufacturing model and distribution network to support future product launches.

RenovaCare is led by CEO Klaus von Goetz, who brings over two decades of experience in medical device development and commercialization. Under his leadership, the company has built a multidisciplinary team of scientists, clinicians and regulatory experts dedicated to transforming wound care through regenerative medicine. RenovaCare’s mission is to deliver innovative therapies that restore skin integrity and improve patient outcomes in markets with significant unmet medical needs.

AI Generated. May Contain Errors.

Receive RCAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovaCare and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCAR Stock News Headlines

The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.tc pixel
RenovaCare Inc.
RenovaCare, Inc. (RCAR)
Best Midsize Car for 2022
Cheapest Car Insurance New Jersey
See More Headlines

RCAR Stock Analysis - Frequently Asked Questions

Shares of RCAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovaCare investors own include Brainstorm Cell Therapeutics (BCLI), ReNeuron Group (RENE), Coherus Oncology (CHRS), Fulcrum Therapeutics (FULC), Gold.com (GOLD), SCYNEXIS (SCYX) and Teva Pharmaceutical Industries (TEVA).

Company Calendar

Today
9/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:RCAR
CIK
1016708
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-127.08

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (OTCMKTS:RCAR) was last updated on 9/6/2026 by MarketBeat.com Staff.
From Our Partners